1. Self-assembled Pt(II) metallacycles enable precise cancer combination chemotherapy.
- Author
-
Zhang P, Zhou Z, Long W, Yan Y, Li Y, Fu T, Liu Y, Zhao Z, Tan W, and Stang PJ
- Subjects
- Animals, Drug Liberation, Drug Synergism, Folic Acid chemistry, Humans, Mice, Nanoparticles, Polymers therapeutic use, Tumor Microenvironment, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols chemistry, Camptothecin administration & dosage, Camptothecin pharmacology, Neoplasms drug therapy, Platinum chemistry, Stilbenes administration & dosage, Stilbenes pharmacology
- Abstract
Combination chemotherapy, which involves the simultaneous use of multiple anticancer drugs in adequate combinations to disrupt multiple mechanisms associated with tumor growth, has shown advantages in enhanced therapeutic efficacy and lower systemic toxicity relative to monotherapy. Herein, we employed coordination-driven self-assembly to construct discrete Pt(II) metallacycles as monodisperse, modular platforms for combining camptothecin and combretastatin A4, two chemotherapy agents with a disparate mechanism of action, in precise arrangements for combination chemotherapy. Formulation of the drug-loaded metallacycles with folic acid–functionalized amphiphilic diblock copolymers furnished nanoparticles with good solubility and stability in physiological conditions. Folic acids on the surface of the nanoparticles promote their internalization into cancer cells. The intracellular reductive environment of cancer cells induces the release of the drug molecules at an exact 1:1 ratio, leading to a synergistic anticancer efficacy. In vivo studies on tumor-bearing mice demonstrated the favorable therapeutic outcome and minimal side effects of the combination chemotherapy approach based on a self-assembled metallacycle.
- Published
- 2022
- Full Text
- View/download PDF